www.turner-white.com Gastroenterology Volume 15, Part 1 11
study. Am J Gastroenterol 2003;98:1931–9.
40. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB.
Temporal trends (1973-1997) in survival of patients with
esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 2003;98:1627–33.
41. Gilani N, Gerkin RD, Ramirez FC, et al. Prevalence of Barrett’s esophagus in patients with moderate to severe erosive esophagitis. World J Gastroenterol 2008;14:3518–22.
42. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on
the management of Barrett’s esophagus. Gastroenterology
43. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-
year) followup of a randomized clinical study comparing
antireflux surgery and omeprazole in gastroesophageal
reflux disease. J Am Coll Surg 2001;192:172–9.
44. Yau P, Watson DI, Devitt PG, et al. Laparoscopic antireflux
surgery in the treatment of gastroesophageal reflux in patients with Barrett esophagus. Arch Surg 2000;135:801–5.
45. Sharma P, McQuaid K, Dent J, et al. A critical review of the
diagnosis and management of Barrett’s esophagus: the AGA
Chicago Workshop. Gastroenterology 2004;127:310–30.
46. Gross CP, Canto MI, Hixson J, Powe NR. Management
of Barrett’s esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol
47. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency
ablation in Barrett’s esophagus with dysplasia. N Engl J
48. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a delphi
process. Gastroenterology 2012;143:336–46.
49. Shaheen NJ, Green B, Medapalli RK, et al. The perception
of cancer risk in patients with prevalent Barrett’s esophagus enrolled in an endoscopic surveillance program. Gastroenterology 2005;129:429-–36.
50. Vieth M, Ell C, Gossner L, et al. Histological analysis of
endoscopic resection specimens from 326 patients with
Barrett’s esophagus and early neoplasia. Endoscopy
51. Tschanz ER. Do 40% of patients resected for barrett
esophagus with high-grade dysplasia have unsuspected
adenocarcinoma? Arch Pathol Lab Med 2005;129:177–80.
52. Gono K, Obi T, Yamaguchi M, et al. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Optics 2004;9:568–77.
53. Sharma P, Bansal A, Mathur S, et al. The utility of a novel
narrow band imaging endoscopy system in patients with
Barrett’s esophagus. Gastrointest Endosc 2006;64:167–
54. Kara MA, Peters FP, Fockens P, et al. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett’s esophagus.
Gastrointest Endosc 2006;64:176–85.
55. Kwon RS, Wong Kee Song LM, Adler DG, et al. Endocytoscopy. Gastrointest Endosc 2009;70:610–3.
56. Kodashima S, Fujishiro M, Takubo K, et al. Ex-vivo study
of high-magnification chromoendoscopy in the gastrointestinal tract to determine the optimal staining conditions for
endocytoscopy. Endoscopy 2006;38:1115–21.
57. Kiesslich R, Gossner L, Goetz M, et al. In vivo histology
of Barrett’s esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol
58. Sharma P, Meining AR, Coron E, et al. Real-time increased
detection of neoplastic tissue in Barrett’s esophagus with
probe-based confocal laser endomicroscopy: final results
of an international multicenter, prospective, randomized,
controlled trial. Gastrointest Endosc 2011;74:465–72.
59. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital
volume and surgical mortality in the United States. N Engl
J Med 2002;346:1128–37.
60. Birkmeyer, JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J
61. Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of
radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991;126:1469–73.
62. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer
surgery: morbidity and mortality results from a prospective
randomized controlled trial comparing D2 and extended
para-aortic lymphadenectomy--Japan Clinical Oncology
Group study 9501. J Clin Oncol 2004;22:2767–73.
63. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic
therapy with porfimer sodium for ablation of high-grade
dysplasia in Barrett’s esophagus: international, partially
blinded, randomized phase III trial. Gastrointest Endosc
64. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic
ablation of Barrett’s esophagus: a multicenter study with
2.5-year follow-up. Gastrointest Endosc 2008;68:867–76.
65. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility
analysis of ablative therapy for Barrett’s esophagus. Gastroenterology 2009;136:2101–14.
66. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History,
molecular mechanisms, and endoscopic treatment of Barrett’s esophagus. Gastroenterology 2010;138:854–69.
67. Peters FP, Kara MA, Curvers WL, et al. Multiband muco-sectomy for endoscopic resection of Barrett’s esophagus:
feasibility study with matched historical controls. Eur J
Gastroenterol Hepatol 2007;19:311–5.